CIRTRAN CORP

CIRX
About the company

CirTran Corporation provides manufacturing, marketing, distribution, and technology services for consumer products, including tobacco products, medical devices, and beverages worldwide. It operates through the Tobacco Line and All Other Product Line segments. The company manufactures, distributes, and sells condoms, electronic cigarettes, electronic cigars, cigars, hookahs, hookah tobacco, energy drinks, water beverages, and related merchandise under the HUSTLER brand name. CirTran Corporation is based in Las Vegas, Nevada.

Country: United StatesPrice: $0.02Market Cap: $99,402

Investment snapshot

12%positive consensus
Scored 1d ago

Positive

2

BUY / PASS

Neutral / negative

2 / 12

NEUTRAL / FAIL

Median fair value

$10.26

+46942.6% vs price

Models with upside

3 / 17

Positive margin of safety

Strongest signal

CIRX undervalued: all 3 models price fair value above $0.02 (median $10.26)

Key risk

No clean pass — all 13 investors flag at least one valuation criterion

Framework analysis

VerdictMeaning
BUYPositive purchase signal: the framework's buy requirements are met.
PASSThe company clears the framework's checklist or screen, but the framework does not produce a buy signal. For valuation frameworks this often means margin of safety is missing, insufficient, or unavailable; some screen-only frameworks have no intrinsic-value BUY state.
NEUTRALNeither a positive nor negative conclusion. It does not mean to hold an existing position.
FAILThe company does not clear the framework's requirements.
RankedRanked strategies do not use PASS: selected cohort is BUY, outside the cohort is FAIL, and unranked is NEUTRAL.

Current investor scores use trailing 12-month flows and the latest balance sheet where supported. Multi-year and EPS tests retain annual history; each framework shows its financial basis below. Intrinsic values use annual financials.

MetricGraham

Defensive Value

Buffett

Quality Compounder

Lynch

GARP

Greenblatt

Magic Formula

Piotroski

F-Score

Dreman

Contrarian Value

Munger

Quality Focus

Pabrai

Dhandho Framework

Akre

Three-Legged Stool

Marks

Risk-Aware Value

Ackman

Activist Value

Templeton

Global Bargain Hunter

Sleep

Scale Economies Shared

Asness

Systematic Factors

Neff

Low-P/E Total Return

Schloss

Asset-Value Discipline

O'Shaughnessy

Systematic Factor Composite

VerdictFAILFAILFAILNot rankedPASSFAILFAILFAILFAILFAILFAILFAILPASSNEUTRALFAILFAILNEUTRAL
Score
AnalysisChecking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…
Intrinsic Value (annual)N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Margin of SafetyN/AN/AN/AN/AN/A+99.9%N/AN/AN/A+99.6%N/A+99.8%N/AN/AN/AN/AN/A
Financial Basis

TTM ended 2026-06-30 · Balance sheet at 2026-06-30 · Annual history · FY 2025

Latest source filing: 2026-08-18

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-06-30

Latest source filing: 2026-08-18

Score computed: 2026-11-14

Annual history · FY 2025 · Balance sheet at 2026-06-30 · TTM ended 2026-06-30 vs 2025-06-30 · TTM ended 2026-06-30

Latest source filing: 2026-08-18

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-04-15

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-04-15

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-06-30 · Balance sheet at 2026-06-30 · Market data at 2026-11-01

Latest source filing: 2026-08-18

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025 · TTM ended 2026-06-30 · Balance sheet at 2026-06-30

Latest source filing: 2026-08-18

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025

Latest source filing: 2026-04-15

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment · Balance sheet at 2026-06-30

Latest source filing: 2026-08-18

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-06-30 · Qualitative assessment

Latest source filing: 2026-08-18

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-06-30 · Balance sheet at 2026-06-30 · Market data at 2026-11-01

Latest source filing: 2026-08-18

Score computed: 2026-11-14

Annual history · FY 2025 · Price history 2025-01-01–2026-11-01 · Balance sheet at 2026-06-30

Latest source filing: 2026-08-18

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment

Latest source filing: 2026-04-15

Score computed: 2026-11-14

TTM ended 2026-06-30 · Balance sheet at 2026-06-30 · Price history 2025-01-01–2026-11-01 · Annual history · FY 2025

Latest source filing: 2026-08-18

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-04-15

Score computed: 2026-11-14

Annual history · FY 2025 · Balance sheet at 2026-06-30

Latest source filing: 2026-08-18

Score computed: 2026-11-14

TTM ended 2026-06-30 · Annual history · FY 2025 · Price history 2025-01-01–2026-11-01

Latest source filing: 2026-08-18

Score computed: 2026-11-14

Where It Passes

  • Valuation models100% pass✓ 3▾

    CIRX undervalued: all 3 models price fair value above $0.02 (median $10.26)

    Dreman fair value$17.15
    ✓Dreman+99.9% margin vs $0.02
    Marks fair value$5.25
    ✓Marks+99.6% margin vs $0.02
    Templeton fair value$10.26
    ✓Templeton+99.8% margin vs $0.02

Where It Falls Short

  • Valuation0% pass✓ 5✗ 23▾

    No clean pass — all 13 investors flag at least one valuation criterion

    Price / 3-yr avg EPS0.0x
    ✓Graham<= 15x
    Price-to-Book Ratio
    ✗Graham<= 1.5x
    P/E x P/B
    ✗Graham<= 22.5
    Basic earnings-growth PEG (dividends excluded)
    ✗Lynch< 1.0 (ideally < 0.5)
    EBIT / Enterprise Value-4.9%
    ✗Greenblatt> 10%
    Earnings Yield + ROC AssessmentEY=-4.9%, ROC=N/A (invested capital <= 0)
    ✗GreenblattBoth EY > 10% and ROC > 25%
    Price / EPS
    ✗Dreman< 12x✗Templeton< 12x (fixed ceiling; proxy for the market's cheapest 40%)
    Price / (CFO / Shares)N/A (negative CFPS)
    ✗Dreman< 8x
    Price / Book Value per ShareN/A (negative BVPS)
    ✗Dreman< 1.2x✗Templeton< 1.5x✗SchlossP/B <= 0.80x (app cutoff)
    Valuation ReasonablenessOE Yield=-648.8%
    ✗MungerP/E < 25 or Owner Earnings Yield > 5%
    P/E or FCF Yield
    ✗PabraiP/E < 15 or FCF Yield > 10%
    P/B or P/E vs. Historical Average
    ✗MarksP/E < 15 or P/B < 2.0
    Discount to Intrinsic Value99.9% (IV=$17.15 vs Price=$0.02)
    ✓Marks>= 20% below intrinsic value
    Price / FCF per Share
    ✗Ackman<= 25
    Price vs. Trailing Low218% of trailing low ($0.01)
    ✗Templeton<= 120% of trailing low (certified split-adjusted live window)
    Net income / market capitalization+2142.14%; #18/6340 (top 0.3%)
    ✓AsnessTop 30% of eligible cross-section✓OshaughnessyTop 10% of eligible cross-section
    Positive book equity / market capitalization-231.3275; #6405/6449 (top 99.3%)
    ✗AsnessTop 30% of eligible cross-section
    Price / Diluted EPS
    ✗NeffP/E <= 15x (app proxy for a P/E 40%-60% below the market)
    (EPS CAGR % + Dividend Yield %) / P/E
    ✗Neff> 0.7 (Neff's published traditional edge)
    Price / Tangible Book Value per ShareN/A (non-positive TBVPS)
    ✗SchlossP/TBV <= 1.00x (app cutoff)
    Book Value per Share Change
    ✗SchlossLatest BVPS >= earliest BVPS over >= 3 years (app rule)
    Revenue / market capitalization+48.5972; #123/5247 (top 2.3%)
    ✓OshaughnessyTop 10% of eligible cross-section
    (Operating cash flow - capex) / market capitalization
    ✗OshaughnessyTop 10% of eligible cross-section
    Trailing six-month price return through the evaluation date+5.36%; #2133/6202 (top 34.4%)
    ✗OshaughnessyTop 10% of eligible cross-section
  • Growth0% pass✓ 2✗ 11▾

    No clean pass — all 8 investors flag at least one growth criterion

    EPS Growth (3-yr avg, 10-yr window)N/A (negative base EPS)
    ✗Graham>= 33% growth
    Basic earnings-growth PEG (dividends excluded)
    ✗Lynch< 1.0 (ideally < 0.5)
    3-5 Year EPS CAGR
    ✗Lynch15-30% (Fast Grower); > 0% to pass
    Inventory Growth vs Revenue GrowthInv: 23.4% vs Rev: 336.7%
    ✓LynchInventory growth < Revenue growth
    EPS Growth Direction$0.00 (2011) -> $-0.14 (2025)
    ✗DremanPositive over recent years
    EPS CAGR
    ✗Dreman> 5% annualized
    Positive Net Income Frequency4/13 years positive
    ✗MarksPositive net income in >= 7 of last 10 years
    3yr Median Revenue Growth-6.0%
    ✗Ackman>= 5%
    Positive EPS Growth Frequency2/5 years with positive EPS growth
    ✗AckmanPositive EPS growth in >= 3 of last 5 years
    5-Year EPS CAGR
    ✗Templeton> 0% (5-year EPS CAGR)
    Revenue growth vs. gross and operating margin trendgross margin 62.3% -> 49.3%, operating margin -0.9% -> -4.1%
    ✗SleepRevenue rising; gross margin flat or falling; operating margin holding
    5-year Revenue CAGR12.5%
    ✓SleepCAGR > 7%
    3-5 Year Diluted EPS CAGR
    ✗Neff7%-20% annualized
  • Profitability6% pass✓ 8✗ 27▾

    15 of 16 flag CIRX's profitability — Graham, Buffett, Lynch +12 more

    Positive EPS (10 years)1/15 years positive
    ✗GrahamPositive EPS every year for 10 years
    EPS Growth (3-yr avg, 10-yr window)N/A (negative base EPS)
    ✗Graham>= 33% growth
    Net Income Positive (10+ years)4/15 years positive
    ✗BuffettPositive every year for 10+ years
    ROE (up to 5-year arithmetic mean)
    ✗Buffett> 15% arithmetic mean (app rule)
    Operating Margin (10-yr trend)-4.1% (latest)
    ✓BuffettStable or rising over 10 years
    Free Cash Flow Proxy$20.3M
    ✓BuffettPositive and growing
    Earnings Variance (10-yr CoV)4.45
    ✗BuffettCoV < 0.3
    Retained Earnings Effectiveness
    ✗Buffett$1 retained -> > $1 market value created
    Basic earnings-growth PEG (dividends excluded)
    ✗Lynch< 1.0 (ideally < 0.5)
    3-5 Year EPS CAGR
    ✗Lynch15-30% (Fast Grower); > 0% to pass
    ROEN/A (negative equity)
    ✗Lynch> 15%
    EBIT / Enterprise Value-4.9%
    ✗Greenblatt> 10%
    Earnings Yield + ROC AssessmentEY=-4.9%, ROC=N/A (invested capital <= 0)
    ✗GreenblattBoth EY > 10% and ROC > 25%
    Net Income / Total Assets-27.91%
    ✗PiotroskiROA > 0
    ROA Change YoY-171.43% -> -27.91% (delta: +143.52%)
    ✓PiotroskiCurrent ROA > Prior ROA
    (CFO / Total Assets) vs ROACFO/Assets=-53.23%, ROA=-27.91%
    ✗PiotroskiCFO/Assets > ROA
    Gross Margin Change YoY64.7% -> 49.3%
    ✗PiotroskiImproved YoY
    Pre-Tax Income / Revenue44.1%
    ✓Dreman>= 8%
    Net Income / Shareholders' Equity
    ✗Dreman> 12%
    Margin of Safety
    ✗PabraiP/B < 1.5 or P/E < 15
    Return on Equity
    ✗AkreROE > 20% (3-year avg)
    Discount to Intrinsic Value99.9% (IV=$17.15 vs Price=$0.02)
    ✓Marks>= 20% below intrinsic value
    Positive Net Income Frequency4/13 years positive
    ✗MarksPositive net income in >= 7 of last 10 years
    Operating Income / Revenue6.3%
    ✗Ackman>= 15%
    Net Income / Shareholders Equity
    ✗Ackman>= 15%
    5-Year EPS CAGR
    ✗Templeton> 0% (5-year EPS CAGR)
    Operating Margin Trend-0.9% (2023) -> -4.1% (2025)
    ✗TempletonNon-negative operating-margin trend over 3 years
    Revenue growth vs. gross and operating margin trendgross margin 62.3% -> 49.3%, operating margin -0.9% -> -4.1%
    ✗SleepRevenue rising; gross margin flat or falling; operating margin holding
    Net income / market capitalization+2142.14%; #18/6340 (top 0.3%)
    ✓AsnessTop 30% of eligible cross-section✓OshaughnessyTop 10% of eligible cross-section
    Gross profit / total assets+87.11%; #200/3702 (top 5.4%)
    ✓AsnessTop 30% of eligible cross-section
    Net income / positive book equity
    ✗AsnessTop 30% of eligible cross-section
    Negative 5-year standard deviation of ROA-4.6949; #5621/5884 (top 95.5%)
    ✗AsnessTop 30% of eligible cross-section
    3-5 Year Diluted EPS CAGR
    ✗Neff7%-20% annualized
    Positive Diluted-EPS Years1/9 years positive
    ✗Schloss>= 70% positive over 5-10 observed years (app rule)
  • Debt & Leverage8% pass✓ 1✗ 14▾

    11 of 12 flag CIRX's debt & leverage — Graham, Buffett, Lynch +8 more

    LT Debt vs Net Current Assets
    ✗GrahamLT Debt <= Net Current Assets
    Debt/Equity & Interest CoverageD/E: N/A (negative equity), IC: 0.4x
    ✗BuffettD/E < 0.5 AND Interest Coverage > 5x
    Total Debt / EquityN/A (negative equity)
    ✗Lynch< 0.33
    Cash - Long-term Debt
    ✗LynchPositive preferred
    LT Debt / Total Assets Change0.00% -> 0.00%
    ✓PiotroskiDecreased YoY
    Current Assets / Current Liabilities0.10
    ✗Dreman> 1.5✗SchlossCurrent ratio >= 1.50x (app cutoff)
    Total Debt / Shareholders' Equity
    ✗Dreman< 0.8✗Templeton< 1.0 (fixed cap; proxy for below-sector-median leverage)✗SchlossD/E < 1.00x
    Debt LevelsN/A (non-positive equity)
    ✗MungerDebt/Equity < 0.5✗AkreDebt/Equity < 0.3
    Interest Coverage & Debt/EBITDAIC=0.4x, D/EBITDA=8.5x
    ✗MarksInterest Coverage > 3x; Debt/EBITDA < 4x
    Total Debt / Shareholders Equity
    ✗Ackman<= 1.0
    Negative debt-to-equity (higher means less debt)
    ✗AsnessTop 30% of eligible cross-section
  • Efficiency13% pass✓ 2✗ 9▾

    7 of 8 flag CIRX's efficiency — Graham, Buffett, Greenblatt +4 more

    Current Ratio0.10
    ✗Graham>= 2.0
    ROIC (3-5 yr avg)
    ✗Buffett> 10%
    ROIC - WACC
    ✗BuffettPositive (WACC = 10%)
    EBIT / (NWC + Net Fixed Assets)N/A (invested capital <= 0)
    ✗Greenblatt> 25%
    Current Ratio Change YoY0.06 -> 0.09
    ✓PiotroskiIncreased YoY
    Revenue / Total Assets Change YoY0.85x -> 1.24x
    ✓PiotroskiImproved YoY
    Current Assets / Current Liabilities0.10
    ✗Dreman> 1.5
    Return on Invested CapitalN/A (non-positive invested capital)
    ✗Munger> 15%
    ROIC (high and growing)FY2023: ROIC=unavailable; FY2024: ROIC=unavailable; FY2025: ROIC=unavailable
    ✗AkreLatest 3 consecutive FYs: ROIC > 15% in each
    Reinvestment Rate x ROIC
    ✗AkreReinvestment Rate * ROIC > 10%
    ROIC (5-year)
    ✗SleepROIC > 12% in a majority of years
  • Verdicts14% pass✓ 2✗ 12▾

    Split decision: 12 FAIL · 2 PASS · 2 NEUTRAL

    Overall verdict
    ✗GrahamFAIL (1/9)✗BuffettFAIL (2/9)✗LynchFAIL (1/7)•GreenblattNot ranked✓PiotroskiPASS (F-Score 5)✗DremanFAIL (1/11)✗MungerFAIL (0/4)✗PabraiFAIL (0/3)✗AkreFAIL (0/6)✗MarksFAIL (2/5)✗AckmanFAIL (1/9)✗TempletonFAIL (1/8)✓SleepPASS (3/6)•AsnessNEUTRAL (Not ranked)✗NeffFAIL (1/6)✗SchlossFAIL (0/7)•OshaughnessyNEUTRAL (Not ranked)
  • Cash Flow20% pass✓ 2✗ 10▾

    8 of 10 flag CIRX's cash flow — Lynch, Piotroski, Dreman +5 more

    Free Cash Flow Proxy$20.3M
    ✓BuffettPositive and growing
    FCF Positive and Growing$-0.1M
    ✗LynchPositive and growing
    Operating Cash Flow$-1.3M
    ✗PiotroskiCFO > 0
    (CFO / Total Assets) vs ROACFO/Assets=-53.23%, ROA=-27.91%
    ✗PiotroskiCFO/Assets > ROA
    Price / (CFO / Shares)N/A (negative CFPS)
    ✗Dreman< 8x
    P/E or FCF Yield
    ✗PabraiP/E < 15 or FCF Yield > 10%
    FCF Positive2/3 years FCF positive
    ✓MarksPositive FCF in majority of recent years
    (OCF - CapEx) / Market Cap
    ✗Ackman>= 4%
    Price / FCF per Share
    ✗Ackman<= 25
    Positive Operating Cash Flow frequency5/13 years positive
    ✗SleepPositive OCF in >= 70% of available years
    Operating Cash Flow - Capital Expenditures
    ✗Neff> $0 (app proxy for a strong fundamental case)
    (Operating cash flow - capex) / market capitalization
    ✗OshaughnessyTop 10% of eligible cross-section

Business & financials

Financial snapshot: annual FY 2025. Current investor scores may use newer quarterly data.

Company Profile

Industry: Beer & Liquor
SIC Sector: Food Products
Size: Micro Cap($99,402)
Revenue: $3.1M+141.1% YoY
Net Income: $-701634.00+73.3% YoY

Financial Snapshot

Operating Margin-4.1%
Return on Equity2.8%
Debt / Equity-0.10
Current Ratio0.09
EPS (Diluted)$-0.14
Shares Retired0.0% / 0.0% 2y

Similar Companies

KOCOCA COLA CO
$427.0B
PEPPEPSICO INC
$198.2B
BUDAnheuser-Busch InBev SA/NV
$167.0B
DEODIAGEO PLC
$56.6B

Shareholder Return

Fiscal 2025

Retired 0.0% of shares last year, 0.0% over two.

Buybacks
—
Dividends
—

Company Financials

Latest TTM and quarters alongside annual years

TTM sums four consecutive quarters and uses the latest quarter-end balances. Quarter columns show three-month results; annual columns show full-year totals. Growth compares the same period a year earlier. EPS is not added for TTM; full-year ratios are blank for quarters.

The latest annual period end is unavailable. Showing the latest fiscal cycle’s quarters; quarter and annual columns may overlap. Quarterly shows the full quarter history.

MetricTTM · 2026-09-30

2025-10-01 – 2026-09-30

Sources · derived quarter values

Derived from cumulative filings: revenue, net income, operating income, gross profit, ebit, pre tax income, interest expense, operating cash flow, depreciation amortization.

Q3 FY 2026

2026-07-01 – 2026-09-30

Sources · derived quarter values

Derived from cumulative filings: operating cash flow, depreciation amortization.

Q2 FY 2026

2026-04-01 – 2026-06-30

Sources · derived quarter values

Derived from cumulative filings: operating cash flow, depreciation amortization.

Q1 FY 2026

2026-01-01 – 2026-03-31

Sources
FY 2025
Sources
  • 10-K · 2026-04-15
FY 2024
Sources
  • 10-K · 2025-04-15
FY 2023
Sources
  • 10-K · 2024-04-19
FY 2022
Sources
  • 10-K · 2023-04-18
FY 2021
Sources
  • 10-K · 2022-04-15
Market Cap$99.4Kcurrent------$113.7Kest.$49.5Kest.$108.8Kest.$136.0Kest.$331.3Kest.
Revenue$5.0M↑289%$663.5K↑48%$1.2M↑596%$1.2M↑152%$3.1M↑141%$1.3M↓20%$1.6M↓6%$1.7M↓41%$2.9M
Operating Income$423.1K↑172%-$47.0K↑72%$160.6K↑183%$36.1K↑183%-$129.7K↑76%-$550.7K↓3592%-$14.9K↑97%-$522.3K↓129%-$228.0K
Net Income$2.3M↑216%-$285.2K↑32%-$107.9K↑81%$2.2M↑1529%-$701.6K↑73%-$2.6M↓113%$20.3M↑1451%-$1.5M↓1290%$126.2K
EPS (Diluted)--$-0.06↑33%$-0.02↑83%$0.45↑1600%$-0.14↑74%$-0.53↓113%$4.10↑41100%$-0.01$0.00
Gross Margin46.0%↓21%34.7%↓12%52.8%↑5%39.9%↓32%49.3%↓24%64.7%↑4%62.3%↑5%59.5%↓8%65.0%
Operating Margin8.4%↑118%-7.1%↑81%13.7%↑112%3.1%↑133%-4.1%↑90%-42.5%↓4501%-0.9%↑97%-30.4%↓289%-7.8%
ROE-9.7%↓227%———2.8%↓74%10.8%↑112%-93.2%↓2709%3.6%↑1248%-0.3%
Total Debt$3.3M↑30%$3.3M↑30%$2.6M↑4%$2.6M↑4%$2.5M↑4%$2.4M↑4%$2.3M↑14%$2.1M↑5%$2.0M
Shareholders' Equity-$23.3M↑9%-$23.3M↑9%-$23.0M↑8%-$22.9M↑7%-$25.1M↓3%-$24.4M↓12%-$21.8M↑48%-$42.1M↓4%-$40.6M
Current Ratio0.09↑40%0.09↑40%0.10↑79%0.10↑59%0.09↑66%0.06↓25%0.07↑80%0.04↑43%0.03
Debt / Equity-0.14↓43%-0.14↓43%-0.11↓14%-0.11↓12%-0.10↓1%-0.10↑7%-0.11↓120%-0.05↓1%-0.05
Operating Cash Flow-$523.3K↑51%-$341.5K↑16%$183.7K↑216%-$59.1K↑87%-$1.3M↓2787%-$46.4K↑36%-$72.6K↓146%$159.3K↓54%$344.5K
Free Cash Flow-------------$81.0K--$340.7K

Score history

Historical Score Timeline

Industry peers

Industry Peers

Similar companies in Beer & Liquor

CIRX vs Peers — Financial Grading

Revenue$3.1MBottom 25%
Net Income$-701634.00Bottom 25%
ROE2.8%Bottom 25%
D/E-0.10Top 25%
Op. Margin-4.1%Bottom 25%
Curr. Ratio0.09Bottom 25%
CompanyMarket CapPriceRevenueNet IncomeROED/EOp. MarginCurr. RatioGrahamBuffettLynchGreenblattPiotroskiDreman
COCA COLA COKO$427.0B$99.25$47.9B$13.1B40.7%1.3728.7%1.463/96/94/71/3F-Score 73/11
PEPSICO INCPEP$198.2B$145.44$93.9B$8.2B40.4%2.4112.2%0.854/96/93/71/3F-Score 56/11
Anheuser-Busch InBev SA/NVBUD$167.0B$84.81$59.3B$6.8B7.8%0.8426.0%0.721/91/93/71/3F-Score 72/11
DIAGEO PLCDEO$56.6B$101.59$28.0B$2.5B22.9%2.1415.5%1.631/94/92/71/3F-Score 45/11
Keurig Dr Pepper Inc.KDP$49.5B$36.34$16.6B$2.1B8.1%0.6321.5%0.642/92/92/71/3F-Score 62/11
AMBEV S.A.ABEV$42.5B$2.76$16.1B$2.8B17.6%0.0426.4%0.961/95/96/73/3F-Score 64/11
CONSTELLATION BRANDS, INC.STZ$24.6B$145.61$9.1B$1.7B20.9%1.2729.8%1.081/92/92/71/3F-Score 55/11
BROWN FORMAN CORPBF-B$14.1B$30.65$3.9B$715.0M17.8%0.6125.5%3.245/96/92/71/3F-Score 75/11